Prestige Consumer Healthcare Inc. (NYSE:PBH) Expected to Post Quarterly Sales of $232.05 MillionNovember 21, 2020 Off By administrator
Wall Street analysts predict that Prestige Consumer Healthcare Inc. (NYSE:PBH) will announce $232.05 million in sales for the current quarter, Zacks reports. Four analysts have made estimates for Prestige Consumer Healthcare’s earnings. The highest sales estimate is $234.10 million and the lowest is $229.80 million. Prestige Consumer Healthcare reported sales of $241.55 million in the same quarter last year, which indicates a negative year over year growth rate of 3.9%. The business is scheduled to issue its next quarterly earnings report on Thursday, February 4th.
According to Zacks, analysts expect that Prestige Consumer Healthcare will report full year sales of $926.00 million for the current financial year, with estimates ranging from $925.00 million to $927.90 million. For the next year, analysts expect that the business will report sales of $939.88 million, with estimates ranging from $929.70 million to $953.80 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of analysts that cover Prestige Consumer Healthcare.
Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings data on Thursday, November 5th. The company reported $0.78 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.72 by $0.06. The company had revenue of $237.42 million during the quarter, compared to the consensus estimate of $227.43 million. Prestige Consumer Healthcare had a return on equity of 13.81% and a net margin of 15.84%. The firm’s revenue was down .3% compared to the same quarter last year. During the same period last year, the company earned $0.68 earnings per share.
Several equities research analysts have recently issued reports on PBH shares. Zacks Investment Research lowered shares of Prestige Consumer Healthcare from a “buy” rating to a “hold” rating and set a $39.00 price target for the company. in a research note on Monday, October 12th. DA Davidson lowered their price target on Prestige Consumer Healthcare from $45.00 to $39.00 and set a “neutral” rating on the stock in a report on Friday, November 6th. BMO Capital Markets upped their target price on shares of Prestige Consumer Healthcare from $106.00 to $112.00 and gave the stock a “market perform” rating in a research report on Friday, November 6th. TD Securities boosted their price objective on shares of Prestige Consumer Healthcare from $115.00 to $125.00 and gave the stock a “buy” rating in a report on Friday, November 6th. Finally, CIBC increased their target price on Prestige Consumer Healthcare from $100.00 to $103.00 and gave the company a “neutral” rating in a report on Monday, November 9th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and two have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $72.43.